Pharmafile Logo

Creative Bioarray

Located at Long Island, New York, Creative Bioarray was founded as biomedical company focused on providing comprehensive biotechnology and pharmaceutical array services and products for high-throughput analysis. Creative Bioarray uniquely pioneers the development of high quality tissue, antibody, protein and cell array technology to efficiently analyze the concurrent expression and function of proteins involved in inflammation, angiogenesis, apoptosis, cell growth, and signal transduction from a single biological sample.

This is a FREE LISTING on PMHUB

Below are full profiles from other companies in related areas

Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop great pharmaceutical brands. We do this by creating Pharmacohesion™.

View Profile

Innovative Trials

Innovative Trials is a leading global clinical trial patient recruitment company. With over 10 years’ of experience, Innovative Trials deploys ‘boots-on-the-ground’ recruitment experts in over 70 countries, addressing individual sites’…

View Profile

Company Details

45-16 Ramsey Road Shirley, New York, NY 11967, United States
+1 631 624 4882

 Latest Content from PMHub 

Innovative Trials suspends services in Russia in response to Ukraine war

Kate Shaw, Founder & CEO of the leading patient recruitment organisation based in Letchworth (UK), on the current Russia-Ukraine situation.

Nucleus Global launches Chrysalis Medical Communications, the network’s newest agency brand in Europe, with a unifying mission

Press Releases | March 30, 2022 | Nucleus Global

Nucleus Global, the largest specialist medical communications network in the world, today launched Chrysalis in Europe with the mission of transforming medical communications together.Stuart Gilbert, Managing Director, said: “Chrysalis’s mission...

Improving diversity in clinical trial patient recruitment

A key requirement for clinical trials is to understand the effect of potential treatments on the patient populations that will benefit most. Despite this, many studies find diverse patient recruitment...

Nucleus X Consulting – where patient engagement meets strategic consultancy

Press Releases | March 29, 2022 | Nucleus Global

Nucleus X Consulting consists of an agile team of specialists that combine expertise in all aspects of patient engagement along with strategic consultancy in rare disease and early-phase medical commercialisation.We...

Could I have a word please…?

Just how important is hard hitting copy?

Learning to invest in doctors’ education

Pharmaceutical companies know doctors want high-value educational content. In a highly pressurised, cost-constrained healthcare environment with increasing demands for value and improved patient outcomes, time-poor doctors are calling out for...

Top 10 Tips for Running a Successful Virtual Event

As I explored in a recent article previously published on Pharmaphorum, the ways that pharmaceutical and scientific communities attend meetings and events completely changed in 2020. Virtual events are rapidly improving, as...

Removing Barriers to Pharmaceutical Accessibility & Affordability Worldwide

Dr. Dhiren Thakker, Founding President and CEO at Med Aditus, shares his insights into how blockchain and other leading-edge technologies can help revolutionize pharmaceutical manufacturing in sub-Saharan Africa and globally....

The Eleven guide to NFTs

Press Releases | March 24, 2022 | 11 London

Non-Fungible Tokens (NFTs) have been making waves in the news lately, specifically around the millions of dollars being exchanged for unique digital art assets. Investors have been queuing up to...

Extraordinary lives: advancing change in rare diseases (Part 2)

In support of Rare Disease Day, we’re excited to launch part 2 of our video series; Extraordinary lives: advancing change in rare diseases.Why is raising awareness of rare diseases so...